NextCure, Inc.
Moat Score — NextCure, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | NextCure's exclusive Yale-licensed FIND discovery platform and its engineered B7-H4 antibody intermediate paired with LigaChem's ConjuAll linker represent real proprietary technology, but LNCB74 is still in early Phase 1 dose escalation with no approved IP-protected product yet generating value, and the underlying B7-H4 target is already being pursued by AstraZeneca, GSK, and BeiGene. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small clinical-stage biotech, NextCure has no manufacturing or R&D cost advantage over competitors; if anything it faces a cost disadvantage against AstraZeneca and GSK's scale, and has had to pause its own cGMP manufacturing facility, relying on the 50/50 LigaChem cost-share purely to make its budget stretch further. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | NextCure has no approved product and therefore no pricing power of any kind; any future pricing power is entirely speculative and contingent on LNCB74 reaching approval and demonstrating meaningful clinical differentiation from larger competitors' B7-H4 programs. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in drug discovery or clinical development; NextCure's value depends solely on the biological and clinical performance of its molecules, not on any user or data network that grows more valuable with scale. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no commercial product, there are no physicians or patients 'switching' to or from NextCure's therapies; this category is not yet applicable and would only become relevant post-approval, which remains years away at best. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The B7-H4 ADC niche already supports multiple well-funded competitors (AstraZeneca, GSK, BeiGene, Mersana), so there is no evidence the space is an efficient-scale niche that deters new entrants; if anything, NextCure is the under-scaled player relative to its rivals, not a protected incumbent. |